CONTEXT: Sex hormones may differ by race/ethnicity in postmenopausal women. Whether racial/ethnic differences also exist among those who are overweight and glucose intolerant is not clear. OBJECTIVES: The objective of the study was to compare sex hormones by race/ethnicity [non-Hispanic white (NHW), Hispanic, African-American (AA)] in overweight, glucose-intolerant, postmenopausal women. DESIGN: This was a secondary analysis of a randomized controlled trial. PARTICIPANTS: Participants included postmenopausal glucose-intolerant women participating in the Diabetes Prevention Program. INTERVENTIONS: Interventions included intensive lifestyle modification (consisting of diet and physical activity) or metformin 850 mg twice a day vs. placebo. MAIN OUTCOME MEASURES: Baseline levels and 1-yr intervention-related changes in SHBG, total and bioavailable estradiol (E2), total and bioavailable testosterone, and dehydroepiandrosterone were measured. RESULTS: At baseline, among women not using estrogen (n = 370), NHW had higher total and bioavailable E2 and testosterone levels than Hispanics independent of age, type of menopause, waist circumference, alcohol intake, and current smoking. NHW also had higher levels of bioavailable E2 and lower levels of SHBG than AA. At baseline, among estrogen users (n = 310), NHW had higher total and bioavailable E2 than Hispanics and higher levels of SHBG than AA after adjustment. At 1 yr, among women not using estrogen, NHW had larger declines in total E2 and bioavailable E2 levels than AA after adjustment for the above covariates, changes in waist circumference, and randomization arm. At 1 yr, among estrogen users, sex hormone changes did not differ by race/ethnicity. CONCLUSIONS: Among postmenopausal women, there were significant race/ethnicity differences in baseline sex hormones and changes in sex hormones.
RCT Entities:
CONTEXT: Sex hormones may differ by race/ethnicity in postmenopausal women. Whether racial/ethnic differences also exist among those who are overweight and glucose intolerant is not clear. OBJECTIVES: The objective of the study was to compare sex hormones by race/ethnicity [non-Hispanic white (NHW), Hispanic, African-American (AA)] in overweight, glucose-intolerant, postmenopausal women. DESIGN: This was a secondary analysis of a randomized controlled trial. PARTICIPANTS: Participants included postmenopausal glucose-intolerantwomen participating in the Diabetes Prevention Program. INTERVENTIONS: Interventions included intensive lifestyle modification (consisting of diet and physical activity) or metformin 850 mg twice a day vs. placebo. MAIN OUTCOME MEASURES: Baseline levels and 1-yr intervention-related changes in SHBG, total and bioavailable estradiol (E2), total and bioavailable testosterone, and dehydroepiandrosterone were measured. RESULTS: At baseline, among women not using estrogen (n = 370), NHW had higher total and bioavailable E2 and testosterone levels than Hispanics independent of age, type of menopause, waist circumference, alcohol intake, and current smoking. NHW also had higher levels of bioavailable E2 and lower levels of SHBG than AA. At baseline, among estrogen users (n = 310), NHW had higher total and bioavailable E2 than Hispanics and higher levels of SHBG than AA after adjustment. At 1 yr, among women not using estrogen, NHW had larger declines in total E2 and bioavailable E2 levels than AA after adjustment for the above covariates, changes in waist circumference, and randomization arm. At 1 yr, among estrogen users, sex hormone changes did not differ by race/ethnicity. CONCLUSIONS: Among postmenopausal women, there were significant race/ethnicity differences in baseline sex hormones and changes in sex hormones.
Authors: Veronica Wendy Setiawan; Malcolm C Pike; Laurence N Kolonel; Abraham M Nomura; Marc T Goodman; Brian E Henderson Journal: Am J Epidemiol Date: 2006-11-07 Impact factor: 4.897
Authors: Rowan T Chlebowski; Zhao Chen; Garnet L Anderson; Thomas Rohan; Aaron Aragaki; Dorothy Lane; Nancy C Dolan; Electra D Paskett; Anne McTiernan; F Alan Hubbell; Lucile L Adams-Campbell; Ross Prentice Journal: J Natl Cancer Inst Date: 2005-03-16 Impact factor: 13.506
Authors: Stefania Lamon-Fava; Junaidah B Barnett; Margo N Woods; Christina McCormack; Judith R McNamara; Ernst J Schaefer; Christopher Longcope; Bernard Rosner; Sherwood L Gorbach Journal: J Clin Endocrinol Metab Date: 2005-05-10 Impact factor: 5.958
Authors: Veronica Wendy Setiawan; Christopher A Haiman; Frank Z Stanczyk; Loïc Le Marchand; Brian E Henderson Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-10 Impact factor: 4.254
Authors: MaryFran R Sowers; Mary Jannausch; Daniel McConnell; Roderick Little; Gail A Greendale; Joel S Finkelstein; Robert M Neer; Janet Johnston; Bruce Ettinger Journal: J Clin Endocrinol Metab Date: 2006-01-10 Impact factor: 5.958
Authors: Elizabeth J Mayer-Davis; Karen C Sparks; Katherine Hirst; Tina Costacou; Jennifer C Lovejoy; Judith G Regensteiner; Mary A Hoskin; Andrea M Kriska; George A Bray Journal: Ann Epidemiol Date: 2004-11 Impact factor: 3.797
Authors: Kristin Wallace; Allan DeToma; David N Lewin; Shaoli Sun; Don Rockey; Carolyn D Britten; Jennifer D Wu; Aissatou Ba; Anthony J Alberg; Elizabeth G Hill Journal: Clin Colorectal Cancer Date: 2016-12-07 Impact factor: 4.481
Authors: Kevin Kalinsky; Katherine D Crew; Susan Refice; Tong Xiao; Antai Wang; Sheldon M Feldman; Bret Taback; Aqeel Ahmad; Serge Cremers; Hanina Hibshoosh; Matthew Maurer; Dawn L Hershman Journal: Cancer Invest Date: 2014-03-07 Impact factor: 2.176
Authors: Catherine Kim; Dana Dabelea; Rita R Kalyani; Costas A Christophi; George A Bray; Xavier Pi-Sunyer; Christine H Darwin; Swaytha Yalamanchi; Elizabeth Barrett-Connor; Sherita Hill Golden; Edward J Boyko Journal: J Clin Endocrinol Metab Date: 2017-09-01 Impact factor: 5.958
Authors: Y Sunakawa; S Cao; M D Berger; S Matsusaka; D Yang; W Zhang; Y Ning; A Parekh; S Stremitzer; A Mendez; S Okazaki; T Wakatsuki; M Azuma; K Shimada; M Watanabe; W Koizumi; A H Wu; H-J Lenz Journal: Pharmacogenomics J Date: 2015-10-27 Impact factor: 3.550